Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Arthritis, Rheumatoid × ISIS104838 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Arthritis, Rheumatoid 1

Interventions

Etanercept 16 Adalimumab 16 Methotrexate 10 Infliximab 8 tocilizumab 7 golimumab 6 Rituximab 6 tofacitinib 5 Abatacept 5 Tumor Necrosis Factor Inhibitors 4 Certolizumab Pegol 4 olokizumab 3 Saline Solution 2 RC-18 2 Nivolumab 2 Leflunomide 2 Antirheumatic Agents 2 veltuzumab 1 upadacitinib 1 secukinumab 1 sarilumab 1 mavrilimumab 1 entecavir 1 baricitinib 1 andecaliximab 1 Vitamin D 1 Vaccines 1 Syringes 1 Surveys and Questionnaires 1 Sulfasalazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00048321 2022-12-05

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Ionis Pharmaceuticals, Inc.

Phase 2 Completed

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡